Epidermolysis Bullosa Simplex, Genodermatosis
Conditions
Keywords
Apremilast, Children, Pediatric
Brief summary
The goal of this clinical trial is to Assessing the Efficacy and Safety of Apremilast in Patients \> 6 years of age with EB simplex generalized . The main question it aims to answer are: describe efficacity of this treatment. Participants will take treatments and have to use bullets during the study period.
Detailed description
The patient will have 7 visits. After Confirmation of inclusion criteria and no exclusion criteria, the study will be explain to the patient after signing the inform consent and be included in the study Treatment Period (Period 1); challenge period This period will be the first treatment period that will occur from 8 weeks. During this period the patient will see the doctor at the hospital, he will perform the study procedures The second period : dechallenge (period 2): All patients stop their treatment for 4 weeks. The second treatment period - rechallenge (period 3) the patient will take the treatment for a second 8 weeks period At week 20 - End of study At each visit: The investigator at each visit compliance to the treatment and adverse events, Measure vital signs and perform clinical examination. The patient will assess the different questionnaires, for the study
Interventions
DRUGApremilast treatment
treatment of apremilast
Sponsors
Centre Hospitalier Universitaire de Nice
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
6 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Male or female patients 6 years or older * Laboratory confirmed diagnosis of EBS-sev due to KRT5 or 14 mutation (autosomal) * Mean daily number of new blisters \>3. * Subject/caregiver agrees not to use any topical therapies other than the investigator approved
Exclusion criteria
* \- EBS lesions requiring oral therapy to treat an infection * Use of any diacerein containing product within 6 months prior to Visit 1 * Use of systemic immunotherapy or cytotoxic chemotherapy within 60 days prior to Visit 1 * Use of systemic steroidal therapy within 30 days prior to Visit 1 * Use of any systemic product that, in the opinion of the investigator, might put the subject at undue risk by study participation or interferes with the study assessments within 30 days prior to Visit 1
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To describe efficacy of apremilast | weeks 20 | number of new blister conting every day |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety of apremilast treatment | weeks 20 | number of SAE |
Countries
France
Outcome results
None listed